NCT03607487 is a Phase 2 clinical trial of INCB054707 in Hidradenitis Suppurativa, sponsored by Incyte Corporation.

Who is sponsoring NCT03607487?

NCT03607487 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03607487?

Interventions in NCT03607487: INCB054707, Placebo.

What condition does NCT03607487 study?

NCT03607487 studies Hidradenitis Suppurativa.

Is NCT03607487 still recruiting?

NCT03607487 is currently completed. Last updated 21 August 2025.

Are results published for NCT03607487?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-21 · How we verify

NCT03607487

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Completed Phase 2 Results posted Last updated 21 August 2025

What this trial tests

Phase 2 trial testing INCB054707 in Hidradenitis Suppurativa in 35 participants. Completed in 13 August 2019.

Timeline

15 October 2018

Primary endpoint
13 August 2019

13 August 2019

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	35
Start date	15 October 2018
Primary completion	13 August 2019
Estimated completion	13 August 2019
Sites	13 locations across Denmark, Canada, Germany

Drugs / interventions tested

INCB054707 — full drug profile →
Placebo

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Incyte Corporation — full company profile →

Who can join

Adults 18 to 75, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Apparent Oral Clearance of INCB054707 Secondary · Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8

To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.

Group	Value	95% CI
INCB54707	5.27	± 2.89

Apparent Oral Volume of Distribution of INCB054707 Secondary · Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8

To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.

Group	Value	95% CI
INCB54707	239	± 85.7

Proportion of Participants Achieving a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit Secondary · Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)

HiSCR defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.

Week 1

Group	Value	95% CI
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	4
INCB054707 at 90 mg	2
Placebo	6
INCB054707 at 30 mg	8
INCB054707 at 60 mg	5
INCB054707 at 90 mg	5

Week 2

Group	Value	95% CI
Placebo	1
INCB054707 at 30 mg	6
INCB054707 at 60 mg	5
INCB054707 at 90 mg	4
Placebo	6
INCB054707 at 30 mg	3
INCB054707 at 60 mg	4
INCB054707 at 90 mg	4

Week 4

Group	Value	95% CI
Placebo	3
INCB054707 at 30 mg	5
INCB054707 at 60 mg	5
INCB054707 at 90 mg	5
Placebo	4
INCB054707 at 30 mg	4
INCB054707 at 60 mg	4
INCB054707 at 90 mg	3

Week 6

Group	Value	95% CI
Placebo	3
INCB054707 at 30 mg	3
INCB054707 at 60 mg	6
INCB054707 at 90 mg	6
Placebo	4
INCB054707 at 30 mg	6
INCB054707 at 60 mg	3
INCB054707 at 90 mg	2

Week 8

Group	Value	95% CI
Placebo	4
INCB054707 at 30 mg	5
INCB054707 at 60 mg	5
INCB054707 at 90 mg	7
Placebo	3
INCB054707 at 30 mg	4
INCB054707 at 60 mg	4
INCB054707 at 90 mg	1

Follow Up

Group	Value	95% CI
Placebo	3
INCB054707 at 30 mg	3
INCB054707 at 60 mg	1
INCB054707 at 90 mg	4
Placebo	4
INCB054707 at 30 mg	6
INCB054707 at 60 mg	8
INCB054707 at 90 mg	3

Early Termination

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit Secondary · Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)

AN defined as abscess and inflammatory nodule count.

Baseline

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	1
Placebo	9
INCB054707 at 30 mg	9
INCB054707 at 60 mg	9
INCB054707 at 90 mg	7

Week 1

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	2
INCB054707 at 90 mg	2
Placebo	7
INCB054707 at 30 mg	9
INCB054707 at 60 mg	7
INCB054707 at 90 mg	5

Week 2

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	3
INCB054707 at 60 mg	5
INCB054707 at 90 mg	4
Placebo	7
INCB054707 at 30 mg	6
INCB054707 at 60 mg	4
INCB054707 at 90 mg	4

Week 4

Group	Value	95% CI
Placebo	2
INCB054707 at 30 mg	3
INCB054707 at 60 mg	6
INCB054707 at 90 mg	5
Placebo	5
INCB054707 at 30 mg	6
INCB054707 at 60 mg	3
INCB054707 at 90 mg	3

Week 6

Group	Value	95% CI
Placebo	3
INCB054707 at 30 mg	2
INCB054707 at 60 mg	5
INCB054707 at 90 mg	5
Placebo	4
INCB054707 at 30 mg	7
INCB054707 at 60 mg	4
INCB054707 at 90 mg	3

Week 8

Group	Value	95% CI
Placebo	4
INCB054707 at 30 mg	4
INCB054707 at 60 mg	4
INCB054707 at 90 mg	5
Placebo	3
INCB054707 at 30 mg	5
INCB054707 at 60 mg	5
INCB054707 at 90 mg	3

Follow Up

Group	Value	95% CI
Placebo	1
INCB054707 at 30 mg	3
INCB054707 at 60 mg	0
INCB054707 at 90 mg	4
Placebo	6
INCB054707 at 30 mg	6
INCB054707 at 60 mg	9
INCB054707 at 90 mg	3

Early Termination

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Mean Change From Baseline in the Hidradenitis Suppurativa Pain Numeric Rating Scale (HS Pain NRS) Scores at Each Visit Secondary · Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)

An 11-point scale used to assess the worst skin pain and the average skin pain due to HS. Skin pain ranges from 0 ("no skin pain") to 10 ("skin pain as bad as you can imagine").

Mean change from Baseline to Week 1

Group	Value	95% CI
Placebo	0.2	± 1.39
INCB054707 at 30 mg	-0.8	± 1.13
INCB054707 at 60 mg	-0.3	± 1.06
INCB054707 at 90 mg	-1.5	± 1.04

Mean change from Baseline to Week 2

Group	Value	95% CI
Placebo	-0.1	± 1.49
INCB054707 at 30 mg	-1.5	± 1.18
INCB054707 at 60 mg	-1.1	± 0.91
INCB054707 at 90 mg	-3.3	± 3.06

Mean change from Baseline to Week 4

Group	Value	95% CI
Placebo	-0.3	± 2.09
INCB054707 at 30 mg	-2.0	± 2.02
INCB054707 at 60 mg	-1.4	± 1.56
INCB054707 at 90 mg	-3.6	± 3.30

Mean change from Baseline to Week 6

Group	Value	95% CI
Placebo	0.0	± 3.49
INCB054707 at 30 mg	-0.9	± 0.90
INCB054707 at 60 mg	-2.0	± 1.55
INCB054707 at 90 mg	-3.4	± 3.05

Mean change from Baseline to Week 8

Group	Value	95% CI
Placebo	0.3	± 2.77
INCB054707 at 30 mg	-2.2	± 2.18
INCB054707 at 60 mg	-1.4	± 1.44
INCB054707 at 90 mg	-3.1	± 3.28

Mean change from Baseline to Follow Up

Group	Value	95% CI
Placebo	2.6	± 2.62
INCB054707 at 30 mg	-2.7	± 2.20
INCB054707 at 60 mg	-0.8	± 0.97
INCB054707 at 90 mg	-1.2	± 1.91

Mean Change From Baseline in the Modified Sartorius Scale Score Secondary · From baseline up to week 8

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of th

Group	Value	95% CI
Placebo	-36.4	± 35.83
INCB054707 at 30 mg	-41.9	± 36.84
INCB054707 at 60 mg	-59.2	± 48.48
INCB054707 at 90 mg	-54.6	± 55.42

Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit. Secondary · Baseline,Weeks 1, 2, 4, 6, 8 and Follow-up (Up to 3 months)

Defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.

Week 1

Group	Value	95% CI
Placebo	-0.1	± 0.38
INCB054707 at 30 mg	-0.1	± 1.27
INCB054707 at 60 mg	-0.8	± 2.39
INCB054707 at 90 mg	-0.3	± 0.49

Week 2

Group	Value	95% CI
Placebo	0.0	± 1.53
INCB054707 at 30 mg	-0.9	± 1.05
INCB054707 at 60 mg	-2.1	± 3.48
INCB054707 at 90 mg	-0.8	± 2.19

Week 4

Group	Value	95% CI
Placebo	-0.9	± 2.79
INCB054707 at 30 mg	-0.6	± 1.01
INCB054707 at 60 mg	-2.0	± 3.57
INCB054707 at 90 mg	-0.9	± 2.53

Week 6

Group	Value	95% CI
Placebo	-1.3	± 2.69
INCB054707 at 30 mg	-0.4	± 1.74
INCB054707 at 60 mg	-2.1	± 3.30
INCB054707 at 90 mg	-0.6	± 2.72

Week 8

Group	Value	95% CI
Placebo	-1.0	± 3.06
INCB054707 at 30 mg	-0.3	± 1.66
INCB054707 at 60 mg	-2.0	± 3.35
INCB054707 at 90 mg	-0.6	± 3.85

Follow Up

Group	Value	95% CI
Placebo	-0.4	± 3.10
INCB054707 at 30 mg	0.1	± 1.69
INCB054707 at 60 mg	-2.2	± 3.19
INCB054707 at 90 mg	-1.3	± 3.86

Proportion of Participants at Each Category of Hurley Stage Secondary · Baseline and Week 8

The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatriza

Baseline

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	4
INCB054707 at 30 mg	9
INCB054707 at 60 mg	5
INCB054707 at 90 mg	7
Placebo	5
INCB054707 at 30 mg	0
INCB054707 at 60 mg	4
INCB054707 at 90 mg	1
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Week 8

Group	Value	95% CI
Placebo	1
INCB054707 at 30 mg	3
INCB054707 at 60 mg	3
INCB054707 at 90 mg	0
Placebo	3
INCB054707 at 30 mg	6
INCB054707 at 60 mg	5
INCB054707 at 90 mg	7
Placebo	3
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	1
INCB054707 at 90 mg	1

Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category During the Treatment Period Secondary · Up to 12 weeks

The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.

Week 1

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	3
INCB054707 at 60 mg	3
INCB054707 at 90 mg	3
Placebo	4
INCB054707 at 30 mg	2
INCB054707 at 60 mg	4
INCB054707 at 90 mg	2

Week 2

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	2
INCB054707 at 90 mg	3
Placebo	3
INCB054707 at 30 mg	4
INCB054707 at 60 mg	3
INCB054707 at 90 mg	1
Placebo	1
INCB054707 at 30 mg	2
INCB054707 at 60 mg	3
INCB054707 at 90 mg	3

Week 4

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	2
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	1
INCB054707 at 90 mg	3
Placebo	3
INCB054707 at 30 mg	2
INCB054707 at 60 mg	1
INCB054707 at 90 mg	1
Placebo	2
INCB054707 at 30 mg	2
INCB054707 at 60 mg	2
INCB054707 at 90 mg	2

Week 6

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	1
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	1
INCB054707 at 90 mg	2
Placebo	3
INCB054707 at 30 mg	2
INCB054707 at 60 mg	3
INCB054707 at 90 mg	2
Placebo	1
INCB054707 at 30 mg	4
INCB054707 at 60 mg	1
INCB054707 at 90 mg	4

Week 8

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	1
Placebo	0
INCB054707 at 30 mg	3
INCB054707 at 60 mg	1
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	3
INCB054707 at 90 mg	1
Placebo	5
INCB054707 at 30 mg	3
INCB054707 at 60 mg	4
INCB054707 at 90 mg	2

Early Termination

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Follow Up

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	2
INCB054707 at 60 mg	2
INCB054707 at 90 mg	1

Actual Measurements in HS-PGIC at Each Visit Secondary · Up to 12 weeks

Week 1

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	3
INCB054707 at 60 mg	3
INCB054707 at 90 mg	3
Placebo	4
INCB054707 at 30 mg	2
INCB054707 at 60 mg	4
INCB054707 at 90 mg	2

Week 2

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	2
INCB054707 at 90 mg	3
Placebo	3
INCB054707 at 30 mg	4
INCB054707 at 60 mg	3
INCB054707 at 90 mg	1
Placebo	1
INCB054707 at 30 mg	2
INCB054707 at 60 mg	3
INCB054707 at 90 mg	3

Week 4

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	2
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	1
INCB054707 at 90 mg	3
Placebo	3
INCB054707 at 30 mg	2
INCB054707 at 60 mg	1
INCB054707 at 90 mg	1
Placebo	2
INCB054707 at 30 mg	2
INCB054707 at 60 mg	2
INCB054707 at 90 mg	2

Week 6

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	1
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	1
INCB054707 at 90 mg	2
Placebo	3
INCB054707 at 30 mg	2
INCB054707 at 60 mg	3
INCB054707 at 90 mg	2
Placebo	1
INCB054707 at 30 mg	4
INCB054707 at 60 mg	1
INCB054707 at 90 mg	4

Week 8

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	1
Placebo	0
INCB054707 at 30 mg	3
INCB054707 at 60 mg	1
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	3
INCB054707 at 90 mg	1
Placebo	5
INCB054707 at 30 mg	3
INCB054707 at 60 mg	4
INCB054707 at 90 mg	2

Early Termination

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Follow Up

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	1
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	1
INCB054707 at 30 mg	2
INCB054707 at 60 mg	2
INCB054707 at 90 mg	1

Proportion of Participants With Change From Baseline Hurley Stage Secondary · Baseline and Week 8

Baseline

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	4
INCB054707 at 30 mg	9
INCB054707 at 60 mg	5
INCB054707 at 90 mg	7
Placebo	5
INCB054707 at 30 mg	0
INCB054707 at 60 mg	4
INCB054707 at 90 mg	1
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Week 8

Group	Value	95% CI
Placebo	1
INCB054707 at 30 mg	3
INCB054707 at 60 mg	3
INCB054707 at 90 mg	0
Placebo	3
INCB054707 at 30 mg	6
INCB054707 at 60 mg	5
INCB054707 at 90 mg	7
Placebo	3
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	1
INCB054707 at 90 mg	1

Number of Treatment-emergent Adverse Events (TEAEs) Primary · Up to 12 weeks

TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Grading was performed using guidance from the CTCAE v 4.03. A grade 3 and above would constitute as "severe".

Grade 1

Group	Value	95% CI
Placebo	2
INCB054707 at 30 mg	6
INCB054707 at 60 mg	4
INCB054707 at 90 mg	1

Grade 2

Group	Value	95% CI
Placebo	2
INCB054707 at 30 mg	2
INCB054707 at 60 mg	2
INCB054707 at 90 mg	3

Grade 3

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	3

Grade 4

Group	Value	95% CI
Placebo	0
INCB054707 at 30 mg	0
INCB054707 at 60 mg	0
INCB054707 at 90 mg	0

Adverse events — posted to ClinicalTrials.gov

Time frame: up to 12 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/9 (0%)

Deaths: 0/9

INCB054707 at 30 mg

Serious: 0/9 (0%)

Deaths: 0/9

INCB054707 at 60 mg

Serious: 0/9 (0%)

Deaths: 0/9

INCB054707 at 90 mg

Serious: 0/8 (0%)

Deaths: 0/8

Total

Serious: 0/35 (0%)

Deaths: 0/35

Other adverse events (54 terms — click to expand)

Reaction	System	Placebo	INCB054707 at 30 mg	INCB054707 at 60 mg	INCB054707 at 90 mg	Total
Fatigue	General disorders	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Folliculitis	Infections and infestations	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—
Disturbance in attention	Nervous system disorders	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—
Vessel puncture site haemorrhage	General disorders	—	—	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—
Acne	Skin and subcutaneous tissue disorders	—	—	—	—	—
Acne cystic	Skin and subcutaneous tissue disorders	—	—	—	—	—
Animal bite	Injury, poisoning and procedural complications	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—
Endodontic procedure	Surgical and medical procedures	—	—	—	—	—
Exercise tolerance decreased	General disorders	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—
Food poisoning	Gastrointestinal disorders	—	—	—	—	—
Hypertriglyceridaemia	Metabolism and nutrition disorders	—	—	—	—	—
Hypoaesthesia	Nervous system disorders	—	—	—	—	—
Hypoglycaemia	Metabolism and nutrition disorders	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—
Migraine	Nervous system disorders	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Pain	General disorders	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—

Data from ClinicalTrials.gov NCT03607487 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F, Meier K, Ghoreschi K. · · 2019 · cited 199× · PMID 31849996 · DOI 10.3389/fimmu.2019.02847
Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD, Kuo FI, Smith PA. · · 2019 · cited 180× · PMID 31649667 · DOI 10.3389/fimmu.2019.02342
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
Alavi A, Hamzavi I, Brown K, Santos LL, et al · · 2022 · cited 61× · PMID 34978076 · DOI 10.1111/bjd.20969
Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.
Del Duca E, Morelli P, Bennardo L, Di Raimondo C, et al · · 2020 · cited 52× · PMID 33182701 · DOI 10.3390/ijms21228436
New perspectives on the treatment of hidradenitis suppurativa.
Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. · · 2021 · cited 47× · PMID 34840709 · DOI 10.1177/20406223211055920
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A, Marinović B, Bukvić Mokos Z. · · 2022 · cited 46× · PMID 35409118 · DOI 10.3390/ijms23073753
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Aarts P, Dudink K, Vossen ARJV, van Straalen KR, et al · · 2021 · cited 37× · PMID 34283386 · DOI 10.1007/s40265-021-01566-2
Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review.
Ocker L, Abu Rached N, Seifert C, Scheel C, et al · · 2022 · cited 36× · PMID 36498816 · DOI 10.3390/jcm11237240

Verify or expand the search:

Other trials of INCB054707

Trials testing the same drug.

NCT05624723 — Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impai · Phase 1 · completed
NCT05624710 — A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Parti · Phase 1 · completed
NCT05061693 — A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis · Phase 2 · completed
NCT05068466 — A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 · Phase 1 · completed
NCT04818346 — A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo · Phase 2 · completed

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03607487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 21 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03607487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03607487

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of INCB054707

Other recruiting trials for Hidradenitis Suppurativa

Other Incyte Corporation trials

Verify against primary sources